Acrivon Therapeutics, Inc. (NASDAQ:ACRV – Get Free Report) has received a consensus rating of “Buy” from the six ratings firms that are currently covering the firm, Marketbeat reports. Six investment analysts have rated the stock with a buy rating. The average 1 year price target among analysts that have covered the stock in the last year is $23.83.
Several research analysts have recently issued reports on ACRV shares. Piper Sandler Companies reiterated a “buy” rating and issued a $30.00 target price on shares of Acrivon Therapeutics in a research note on Friday, September 6th. JMP Securities reaffirmed a “market outperform” rating and issued a $17.00 price objective on shares of Acrivon Therapeutics in a research report on Monday, September 16th. LADENBURG THALM/SH SH raised Acrivon Therapeutics from a “neutral” rating to a “buy” rating and set a $16.00 target price for the company in a report on Monday, September 16th. BMO Capital Markets reaffirmed an “outperform” rating and set a $28.00 price target (up from $25.00) on shares of Acrivon Therapeutics in a report on Monday, September 16th. Finally, HC Wainwright reiterated a “buy” rating and issued a $22.00 price objective on shares of Acrivon Therapeutics in a report on Monday, September 16th.
Check Out Our Latest Report on ACRV
Institutional Trading of Acrivon Therapeutics
Acrivon Therapeutics Stock Up 4.4 %
ACRV stock opened at $7.29 on Friday. The business has a 50 day moving average of $7.92 and a 200 day moving average of $7.86. Acrivon Therapeutics has a twelve month low of $3.19 and a twelve month high of $11.90. The firm has a market cap of $225.09 million, a PE ratio of -2.53 and a beta of 0.78.
Acrivon Therapeutics (NASDAQ:ACRV – Get Free Report) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.08. On average, research analysts expect that Acrivon Therapeutics will post -2.4 earnings per share for the current fiscal year.
About Acrivon Therapeutics
Acrivon Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates.
Featured Stories
- Five stocks we like better than Acrivon Therapeutics
- How to Effectively Use the MarketBeat Ratings Screener
- 3 Micro-Caps Set for Major Moves: Balancing Risk and Opportunity
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Autodesk Named a “Top Pick” by Morgan Stanley—Is It Time to Buy?
- What Does a Stock Split Mean?
- 4 Quirky ETFs With Big Potential for Impressive Gains
Receive News & Ratings for Acrivon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acrivon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.